Zai Refractory SCLC (Small Cell Lung Cancer)

Purpose of this Study

We are doing this study to find the safest and most effective dose of an experimental drug called ZL-1310 (the study drug). We want to know if this drug can be beneficial for people with small cell lung cancer (SCLC) that progressed after at least one round of chemotherapy.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with SCLC that did not respond to treatment
  • Have received at least one line of chemotherapy
For more information about who can join this study, please contact the study team at annemarie.peters@duke.edu.

What is Involved?

Description

If you choose to join this study, you will get the study drug once every 3 weeks. The drug is given as an intravenous (IV) infusion. The study drug will be given at various doses during the study. Your dose of study drug will depend on when you join the study. You will continue to receive the study drug for as long as the study doctor and you feel that you are getting a benefit.

Study Details

Full Title

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

Principal Investigator

Jeffrey
Clarke

Protocol Number

PRO00114821

NCT ID

NCT06179069

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov